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1 Introduction 
Animal safety testing for new medicines is arguably the most difficult use of 
non-human animals (hereinafter referred to as animals) to challenge, for two 
reasons: first, it is required by governments (regulatory testing); second, pro­
tecting patients is a vital goal, and it seems intuitively obvious that animal 
tests must protect patients. Animal testing became institutionalized in the 
mid twentieth century (Parke, 1994) in response to early drug disasters, with 
the aim of preventing further tragedies. However, even the laudable aim of 
protecting patients cannot justify animal testing, unless it is the most effec­
tive means to ensure the safety of medicines. European Union (EU) law (Euro­
pean Parliament, 2010, Directive 2010/63/EU) states that animals must not be 
used if a non-animal method could achieve the same purpose. So, it is crucial 
to know how well animal tests predict the safety of medicines, and whether 
any other methods are equally or more predictive. In addition to the question 
of predictive value, other important issues must also be taken into consider­
ation, including the efficiency of different methods in terms of time and costs; 
and the ethical acceptability of using animals, if their use is deemed to be of 
irreplaceable value. 
The issue of whether animals should be used as human surrogates for safety 
testing is highly contentious; individual views range from no use of animals 
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is acceptable, to any use is justified if it is ultimately for the benefit of human 
health. In a 2016 Ipsos Mori poll for the United Kingdom government, 35°/o of 
respondents felt that "animals should not be used in any scientific research 
because of the importance I place on animal welfare"; and 51% felt that it is 
unacceptable to use animals to test chemicals that could harm plants or the 
environment (Clemence and Leaman, 2016). In the United States (us), a 2017 
Gallup poll found that 44% of adults considered medical testing on animals to 
be morally wrong (Jones and Saad, 2017). A 2015 survey by the us Pew Centre 
found that 50% of citizens "oppose the use of animals in scientific research" 
(Pew Research Center, 2015). Thus, it is questionable whether the continued 
use of animals in research or testing has a mandate from society. What is clear 
is that their use should be replaced as soon as scientifically possible (European 
Parliament, 20101 Recital 10 ), which brings us back to the question of their 
effectiveness relative to other methods. 
Before any new methods can be approved for use in regulatory safety testing, 
they must be shown to be at least as effective as the methods they are designed 
to replace, a logic that cannot be faulted. However, herein lie a number of 
problems. First, we do not know how valuable existing animal-based methods 
actually are, as none have ever been formally validated in the manner required 
for potential replacements. One reason for this is that the formal process of 
test-method validation is so slow, expensive, and demanding, in its current 
format, that it represents an effective block to testing existing accepted meth­
ods and a significant barrier to testing new methods. The situation is further 
complicated by the fact that the "gold standard" with which new data must be 
compared, is usually animal data that is of unknown value. We strongly believe 
that the most relevant gold standard should be human data. 
In this chapter, we propose a new, pragmatic approach that could accelerate 
the replacement of most, if not all, regulatory animal tests with superior tests 
based on human biology. We also propose that changes to the requirements 
for safety testing, issued by the us Food and Drug Administration (FDA), must 
be made in order to enable the use of superior new tests, which are currently 
disadvantaged by the outdated language of the regulations. But first, it is 
imperative to establish some level of understanding of the efficacy of existing 
animal-based methods in order to know whether any possible replacement is 
better or worse. 
2 Leaming from Clinical Experience 
In order to quantify, as best as we can, the effectiveness of animal tests for pre­
dicting the safety of medicines, we can begin by assessing about half a century 
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of clinical experience. We have a significant amount of information gleaned 
from the use of approved medicines in human subjects and can identify, for 
such medicines, where animal-based testing failed to predict human safety 
issues; and whether non-animal methods now exist that would be able to iden­
tify the toxic effects that were missed by animal tests. 
Many medicines that have been judged safe enough for testing in humans, 
following all the required safety tests in vitro, and in at least two species of 
animals, have gone on to cause serious adverse reactions in the first volun­
teers to try them: participants in clinical trials. The most infamous examples 
include the trials of the candidate medicines TGN1412 in the UK, BIA 10-2474 in 
France, and fialuridine in the us. TGN1412 is a monoclonal antibody that was 
intended to treat B cell chronic lymphocytic leukemia and rheumatoid arthri­
tis. The clinical trial, in London in 2006, hit headlines when all six young men 
in the Phase I ( safety assessment) trial were rushed to intensive care with mul­
tiple organ failure. Miraculously, they all survived; but they were told that they 
face "a lifetime of contracting cancers and all the various autoimmune diseases 
from lupus to MS, from rheumatoid arthritis to ME" (Leppard, 2006). TGN1412 
was shown to be safe in monkeys at doses 500 times higher than those that 
nearly proved fatal to the volunteers (St. Clair, 2008). 
InJanuary 2016, a Phase I study of the drug BIA 10-2474 conducted in Rennes, 
France, left one initially healthy volunteer dead, and four volunteers with seri­
ous neurological damage ( Sharav, 2016 ). The drug was intended to target a wide 
range of conditions including pain, hypertension, multiple sclerosis, obesity, 
and cancer. Experts convened by the French National Agency for Medicines 
and Health Products concluded that the compound being tested had caused 
an "astonishing and unprecedented" reaction in the brain. Why this was not 
clear in early trials on animals is "inexplicable," according to the expert panel's 
report (Bisserbe, 2016). The drug had been tested in mice, rats, dogs, and mon­
keys, with few ill effects, despite doses up to 650 times stronger than those giv­
en to the volunteers (Temporary Specialist Scientific Committee, TSSC, 2016). 
A subsequent study indicates that an off-target effect, which can be species 
dependent, may explain why animal tests in multiple species did not identify 
the deadly neurological effects (van Esbroeck et al., 2017). The off-target effect 
could only be found using human cells in vitro and in humans. 
In 1993, a combined Phase I/Phase II clinical trial ( to test both safety and 
effectiveness) of fialuridine, a potential hepatitis B treatment, conducted by 
the National Institutes of Health (NIH) in the us, caused unexpected and dev­
astating reactions, such as jaundice, liver failure, and multiple organ failure. 
Five of the 15 participants died. Emergency liver transplants saved two others. 
Previous toxicity tests in animals, including a six-month trial in dogs, had given 
the drug the green light for testing in humans (Thompson, 1994). 
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Many more medicines have passed both preclinical (mainly animal-based) 
safety tests and human clinical trials and still gone on to cause serious adverse 
reactions in patients. This illustrates how difficult it is to predict safety for 
humans, in general, and even more so for particular members of the human 
population. There is enormous genetic variability between people, and indi­
vidual reactions will vary with age, sex, ethnicity, health, diet, environment, 
and unique genetic characteristics. Adverse drug reactions (ADRs) are now a 
leading cause of death, killing 197,000 people in the EU each year (European 
Commission, 2008), and over 125,000 in the us (Light, 2015). In addition to this 
devastating human cost, the financial cost of AD Rs is astronomical, calculated 
at €79 billion per annum in the EU (European Commission, 2008). A study of 
new drugs approved by the us FDA between 2001 and 2010 found that 32% 
were affected by a post market safety event (Downing et al., 2017 ). Another 
study of all 454 drugs approved in the us and Canada from 1992 to 2011, found 
that 52% ( 236 drugs) were either withdrawn from the market or restricted by 
a serious safety (black box) warning within the 20-year period (Rawson, 2013). 
Black box warnings are reserved for ADRs that may lead to death or serious 
injury. Half of them are detected and documented within seven years after 
drug approval, during which time their market uptake and sales volume may 
be explosive. There is a compelling argument that "when safe and effective the­
rapies already exist, any new drug should be considered a black box" (Lasser et 
al., 2002). When the costs of withdrawn and restricted drugs, as well as failures 
during development, are factored into the total cost of developing a successful 
new drug, this results in an estimated average of us$4 billion and could reach 
as high as us$12 billion (Herper, 2012). 
It is argued that most AD Rs that were not detected in clinical trials are very 
rare and/or idiosyncratic, i.e. unique to the individuals who suffered them and, 
therefore, impossible to identify until large numbers of people are exposed to 
the drug, once it is on the market. The implication of this position, accepted 
by our governments, is that we are powerless to prevent rare or idiosyncratic 
AD Rs and must simply accept them as an unavoidable risk of medicine. The 
problem is that even if an adverse reaction is rare, when millions of people 
are taking a drug, large numbers will be affected. Not only are hundreds of 
thousands of people killed, it is estimated that a total of over 80 million AD Rs 
result in 2.7 million hospitalizations each year; in addition, pain, discomfort 
and dysfunction affect physical or cognitive function and can lead to falls and 
cause potentially fatal vehicle accidents (Light, 2015). While it can be argued 
that responsibility for failing to protect participants in clinical trials from 
dangerous drug candidates lies mainly with animal testing, neither animal 
tests nor human trials have been able to prevent the large numbers of ADRs 
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documented above. Clearly, it is imperative to examine all aspects of safety 
testing, to find every weak point, and to take action to address them all. 
3 Clinical Trial Flaws 
Many problems with clinical trials have been identified, and are being 
addressed to varying degrees (Evans, Thornton and Chalmers, 2006; Goldacre, 
2012 ). For example, most volunteers in Phase I trials are young men, who are 
not representative of the often elderly and/or female patients who will be 
taking the medicines (Abadie, 2010; Johnson et al., 2014). The conduct and 
reporting of trials are beset by a host of biases, such as selective reporting of 
results, to emphasize benefits and disguise risks; and non-publication of trials 
where the desired outcomes were not achieved ( Goldacre, 2012; Harris, 2017 ). 
In biomedical research as a whole, 235 types of bias have been documented 
( Chavalarias and Ioannidis, 2010 ). Many doctors have been campaigning for 
many years to tackle these biases, which make a mockery of the evidence base 
for medical treatments. Doctors and patients are unable to choose the best 
treatments without full, unbiased disclosure of the magnitude of their bene­
fits as well as their risks. With UN endorsement, the AllTrials campaign (2016) 
has published a roadmap towards ensuring that all clinical trials are properly 
reported to improve the evidence base for medicine, which is currently badly 
incorrect and incomplete. 
4 Preclinical Animal Tests 
To assess the performance of preclinical animal tests, the most direct com­
parison is between data obtained during preclinical (animal) and clinical 
(human) trials. We have already mentioned three extreme examples of disas­
trous clinical trials, where animal tests failed to predict toxicity with devastat­
ing consequences. But are these isolated examples, and do animal tests usually 
predict serious toxicities before they manifest in people? This is difficult to 
answer quantitatively because compounds that are shown to be toxic in ani­
mal tests do not usually progress to clinical trials. However, we do know that 
95% of potential new drugs fail during clinical trials (Arrowsmith, 2012 ), either 
because of toxicities that were not predicted, or because they lack the thera­
peutic efficacy that was predicted. Data obtained by Freedom of Information 
legislation shows that from 2010-2014, 7,187 people in the UK suffered seri­
ous unexpected AD Rs during clinical trials and 761 died, although none of the 
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deaths could be proven to have been "directly caused" by the test drug (Bagot, 
2015). More than 2,600 patients participating in clinical trials in India died 
between 2005 and 2012, and nearly 12,000 suffered serious adverse effects. Of 
these, 80 deaths and more than 500 serious adverse effects were directly attrib­
uted to the drug being trialed (Nair, 2015). Clearly the record of animal tests in 
predicting safety is poor. 
Another example that illustrates the dangers of both misleading preclini­
cal animal studies and non-publication of clinical trials is lorcainide, which 
is estimated to have killed over 100,000 people in the us alone over the course 
of the 1980s (Bruckner and Ellis, 2017 ). Lorcainide and other anti-arrhythmic 
drugs (most of which have since been withdrawn) were prescribed routinely 
to patients recovering from heart attacks, on an assumption, bolstered by the 
strength of their effectiveness against experimentally induced arrhythmias in 
animals, that they would help to prevent early deaths. A clinical trial in 1980 
indicated that, in fact, they caused more deaths; but the trial was not published 
until 13 years later, to the great regret of the authors, who realize that they could 
have helped avert tens of thousands of unnecessarily early deaths (Hampton, 
2015). 
An important point that must be made is the difference between predict­
ing the presence or the absence of toxicity. It seems intuitively obvious that 
if a compound is overtly toxic for an animal, it is not unreasonable to suspect 
that it will also be toxic in humans. In a series of studies, Bailey, Thew and Balls 
(2013, 2014, 2015) examined the likelihood that such suspicions would be cor­
rect. They analyzed a data set of 2,366 drugs, for which both animal and human 
data are available, in the most comprehensive analysis of publicly available 
animal toxicity data ever compiled. Crucially, they used the appropriate statisti­
cal metrics of likelihood ratios, for the first time, to question critically the value 
of the use of the main preclinical animal species (i.e., rats, mice, rabbits, dogs, 
and monkeys) in the testing of new human pharmaceuticals. They found that 
the presence of toxicity in animal tests indeed shares some degree of correla­
tion ( above random chance) with the presence of toxicity in humans, although 
such correlation is too variable to be regarded as predictive, as has been dem­
onstrated by many previous studies (Fourches et al., 2010; Geerts, 2009; Green, 
2015; Hackam and Redelmeier, 2006; Heywood, 1990; Igarashi, 1994; Ioannidis, 
2012; Knight et al., 2006; Matthews, 2008; Pound et al., 2004; Pound and Brack­
en, 2014; Perel et al., 2007; Salsburg, 1983; Seouk et al., 2013; Spriet-Pourra and 
Auriche, 1994; Wall and Shani, 2008, van Meer et al., 2012 ). More importantly, 
they found that animal tests have essentially no ability to predict the absence 
of toxicity, the very reason for their use in preclinical testing: candidate drugs 
proceed to testing in humans when no toxicity shows up in tests on animals. 
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So, while animal tests undoubtedly prevent some toxic compounds from reach­
ing humans, they cannot predict safety for humans. Thus, as we have seen, 
their use creates a false sense of security. A study published in 2012 found that 
animal tests missed 81% of the serious side effects of 43 drugs that went on to 
harm patients ( van Meer, 2012 ). This is disastrous not only for patients but also 
for the pharmaceutical industry, which is in crisis and urgently needs to stem 
the unsustainable rate of late-stage attrition of new medicines. 
In addition to letting dangerous medicines slip through the net ( through 
false negative results), promising medicines may be wrongly discarded due to 
animal toxicities that do not affect humans (false positives). Clear examples of 
this are few, as any compound causing AD Rs in animals is extremely unlikely to 
progress to the clinic; therefore, its safety profile in humans remains unestab­
lished. However, there are examples. Glivec, an effective cancer treatment, 
was almost abandoned during development, as it caused liver damage in dogs. 
Fortunately, its remarkable success in human cells in vitro and in early trials 
in leukemia patients enabled its continued development (Capdeville, 2002). 
Similarly, tamoxifen was almost lost as a cancer treatment because it causes 
liver tumors in rats (Carthew, 1995). Evidence for this may also be gleaned 
from drugs introduced before rigorous safety testing became mandatory. For 
example, aspirin, introduced over a hundred years ago, has proved useful for 
pain treatment ever since, but it is highly doubtful it would ever have appeared 
had it been subjected to modem animal-based safety testing (Hartung, 2009). 
Other such examples include, benzodiazepines, methylxanthines, such as 
caffeine, and beta-blockers. It is a similar story with many foodstuffs, such as 
chocolate and garlic, which are well tolerated by humans but prove toxic to 
dogs and cats (Cortinovis and Caloni, 2016). 
Furthermore, not all failures in animal studies involve adverse events. Many 
reflect a lack of apparent efficacy in the chosen animal species, a finding that 
usually consigns a prospective candidate to the waste bin. However, on oc­
casion, a "failed" compound has a champion, sufficiently dogged to proceed 
despite such a setback. A particularly good example of this are statins (Endo, 
2010 ), the best selling drugs in history, which nearly never emerged from 
preclinical testing. Based on the belief that elevated levels of cholesterol in 
the body are, in some way, responsible for coronary heart disease, many ap­
proaches to reducing circulating cholesterol have been explored; one of these 
was through inhibition of HMG-CoA reductase, a key enzyme in cholesterol 
biosynthesis. In 19761 a report of the first statin, compactin, was published 
(Endo et al., 1976), describing how it inhibited this key enzyme and reduced 
cholesterol synthesis in isolated mammalian cells. Unfortunately, when tested 
in rats, this compound proved to be without effect on serum cholesterol levels 
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(Endo, 2010 ); and if not for the persistence of the scientists working on the 
project, this would have been the end of the story. However, despite its lack 
of effect in rats, compactin was, by chance, found to lower circulating levels 
of cholesterol in chickens and, subsequently, in other animal species; and the 
race to develop the ultimate statin was on. Although statins' effectiveness in 
saving lives is now controversial ( de Lorgeril and Rabaeus, 2015), there is no 
doubt of their effectiveness in lowering cholesterol in humans. 
It is hard to imagine a world without antibiotics, the most life-saving class 
of drugs ever discovered. Yet, the world's first antibiotic, penicillin, was almost 
lost to humanity because Alexander Fleming concluded that its rapid clearance 
from the bloodstream in a rabbit would prevent it from being systemically 
effective (Hare, 1982 ). For twelve years following his discovery of "mould juice", 
Fleming pursued its use merely as a topical antiseptic, until Florey and Chain 
resurrected interest in its greater potential. Fleming later commented to his 
student, Dennis Parke, who became an extremely influential pioneering tox­
icologist: "How fortunate we didn't have these animal tests in the 1940s, for 
penicillin would probably never have been granted a license, and possibly the 
whole field of antibiotics might never have been realised" (Parke, 1994). 
We have discussed, above, examples of false negatives and false positives for 
safety, as well as false negatives for efficacy. Finally, there are many examples 
of false positives for efficacy, i.e. drugs that were effective in animal tests but 
turned out to be ineffective in humans. They include the vast majority of new 
cancer treatments, which have one of the highest failure rates (96%) in clinical 
trials (Hutchinson and Kirk, 2011); all putative disease-modifying treatments 
( more than 300) for Alzheimer's disease to date (Langley, 2014; Lowe, 2017 ); 
more than 100 candidate AIDS vaccines, all of which were effective in non­
human primates, as well as other animal models (Sheets et al., 2016); more than 
100 drugs for stroke ( Collaborative Approach to Meta-Analysis and Review of 
Animal Data from Experimental Studies, CAMARADES, 2017); and 150 drugs for 
sepsis, the leading cause of death in intensive care units (Seok et al., 2013). 
The CAMARADES group was founded to study the translatability of stroke 
studies from animals to humans, and later expanded to include a number of 
other diseases that share a high rate of translational failure. They have found 
that the poor quality of animal studies confounds research in all areas they 
have studied, so far (cAMARADES, 2017). These failed treatments have been 
tested on patients in clinical trials. When the director of the us NIH, Dr. Fran­
cis Collins, learned of the poor quality of the animal studies that led to clinical 
trials of treatments for amyotrophic lateral sclerosis (ALS, also known as motor 
neuron disease), he said: "Humans were being put at risk based on that kind 
of data, and that took my breath away" (Harris, 2017). This reproducibility crisis 
is now receiving much attention, and many initiatives have begun to attempt 
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to improve standards and the quality of animal research and reporting (Harris, 
2017). However, a review of developments in the field of stroke found that, de­
spite researchers' adherence to recommendations intended to improve the 
quality of preclinical stroke studies for over 10 years, there is no evidence of an 
increased rate of successful translation (Sutherland et al., 2012). It is possible 
that many years and many precious resources will be invested in attempts to 
surmount a problem that may ultimately be insurmountable, due to inherent 
interspecies differences in crucial genetic and biochemical systems. Dr. Fiona 
Godlee, Editor of British Medical Journal, posed the pivotal question: "Where 
would you place the balance of effort: investment in better animal research or 
a shift in funding to more clinical research?" (Godlee, 2014). 
5 Other Preclinical Tests in Current Use 
Preclinical testing also includes a number of in vitro and in silico ( computer 
modeling) methods, whose record of predicting safety must also be acknowl­
edged as lamentable. Indeed, the UK government always uses this argument 
in defense of animal testing, stating that "prior to testing in animals, new 
drugs are tested in batteries of in silico and in vitro tests, including, where 
available and validated, tests using human tissue samples" (uK Department 
of Health, 2012 ). However, many of these tests are based on animal cells and 
tissues; and even the human-based ones generally do not represent the latest 
state of the art models, which have long ago moved on from 2D to 3D models 
and recognized the importance of incorporating more realistic physiological 
features, such as multiple interconnected organs, metabolic activity, and fluid 
circulation, among others. Technologies are now becoming available that can 
identify toxic liabilities more accurately than animal tests and furthermore, 
some of them are able to identify subtle signals of toxicities that only manifest 
in rare individuals (Xu et al., 2008). This could enable the detection of poten­
tial rare ADRs that are currently unpredictable (Kenna, 2017). Thus, these hu­
man biology-based technologies should be recognized as a truly disruptive (i.e. 
revolutionary) technology, with the potential to transform toxicology from an 
imprecise science based on inter-species extrapolations to a predictive science 
based on a deep understanding of human pathways of toxicity. A particularly 
powerful approach has recently been described by Theil et al. ( 2017 ), in which 
they use a system to "contextualize in vitro" data to reflect an in vivo situation 
in patients through computer modeling, using data derived from both human 
cells and clinical experience. A system such as this allows the identification of 
potential biomarkers of toxicity, and the use of these biomarkers in an in vitro 
setting to predict potential toxicity in clinical use. 
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6 Non-animal Technologies 
Remarkable scientific advances have created a new generation of more rel­
evant and predictive toxicological tools. They include human tissue created by 
reprogramming cells from people with the relevant disease ( dubbed patient 
in a dish); organ on a chip devices, where living human tissue samples on a 
silicon chip are linked by a circulating blood substitute; a variety of comput­
er modeling approaches, such as virtual organs, patients, and clinical trials; 
and microdosing studies, where tiny doses of drugs given to volunteers allow 
scientists to study their metabolism in humans, safely and with unsurpassed 
accuracy. There are also humbler, but no less valuable, studies in ethically 
donated "waste" tissue. Together, these innovations provide invaluable insight 
into the functioning of the integrated human system. Such tests are frequent­
ly able to detect side effects that were missed by preclinical animal tests. For 
example: 
- A micro-liver ( called HepatoPac) comprising human liver cells is able to 
predict liver damage from fialuridine, the potential hepatitis B treatment 
that killed five patients in the devastating 1993 clinical trial (Baker, 2011 ). 
Furthermore, the same technology is able to identify many other liver-toxic 
drugs that were missed by animal testing (Xu et al., 2008). 
- Following the trial of TGN1412, a method using human cells was rapidly 
developed to model the cytokine storm experienced by the volunteers (Steb­
bings et al., 2007 ). 
- The us government's initiative, Toxicology in the 21st Century (Toxz1), has 
tested 10,000 chemicals using a panel of human cell-based assays (National 
Center for Advancing Translational Sciences, 2016). These are automated 
high-throughput screening assays that expose cells to chemicals and then 
screen them for changes that could suggest toxic effects. The use of this pan­
el of assays enabled the identification of important safety aspects of drugs 
and chemicals "markedly better" than toxicity tests in animals (Huang et al., 
2016). The human in vitro data were mainly assessed against rodent data, as 
human in vivo data are sparse. As expected, the Toxz1 data better predicted 
human toxicity endpoints than rodent data. 
Non-animal tests are often faster and cheaper, as well as more accurate and 
reliable (Balijepalli and Sivaramakrishan, 2017; Bracken, 2009; Gamer et al., 
2017; Krul, 2014; NIH, 2008). Some of the more valuable technologies are ex­
pensive, but worth it-there is nothing more expensive than getting the wrong 
answer. Human tissue company, Biopta (2017), estimates an average saving of 
US$7 for every US$1 invested in predictive human assays. Director of the us 
NIH, Dr. Francis Collins, recently predicted before us Congress that within 10 
years, human biochips "will mostly replace animal testing for drug toxicity and 
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environmental sensing, giving results that are more accurate, at lower cost, 
and with higher throughput" (us Senate Committee on Appropriations, 2016). 
However, new methods will not automatically implement themselves. Phar­
maceutical companies would make much greater use of them if governments 
encouraged it, but inflexible requirements for animal tests are a major de­
terrent. Reliance on animals is so entrenched and institutionalized, that the 
system is "locked-in" (Frank, 2004 ). Intervention is necessary to overcome the 
many factors contributing to entrenchment against change. 
7 Validation 
Quite correctly, new technologies must be shown to be robust, reliable, and fit 
for purpose before they can be recommended for use in any regulatory safety­
testing regime. The current validation process involves testing by several differ­
ent laboratories and is tremendously demanding, taking an average of 10 years 
and costing up to US$1 million (Hartung, 2013). This approach protects the sta­
tus quo by making the bar for acceptance so high and so unaffordable for small 
technology providers. Moreover, in this fast-moving field, by the time a new 
technology has finally been validated, it will already have been superseded. 
Most ironically, new technologies are assessed on how well they can predict 
the "gold standard" animal data; thus ensuring that they cannot succeed, if the 
drug affects animals differently from humans, which we now know is very of­
ten the case (Hartung, 2007, 2010; Leist et al., 2012 ). The very concept of the use 
of animal data as a useful standard is fundamentally flawed, as no species is 
truly representative of any other (Hartung, 2009; Wang & Gray, 201s; Perlman, 
2016). Indeed the ability of rats to predict for carcinogenicity in mice has been 
shown to be useful in less than 60% of cases (Gray et al., 1995). 
8 A Way Forward: Pragmatic Evaluation 
The need for better ways to protect the public from the ever-increasing epidem­
ic of AD Rs is so urgent that a new approach to implementing more predictive 
methods is critical. This is now widely recognized and much attention is 
being devoted to making validation more flexible. The FDA is considering ac­
cepting methods that have been through a process of "qualification", rather 
than traditional validation (Food and Drug Administration, FDA, 2017 ). Oth­
ers have suggested streamlining validation, through greater use of reference 
chemicals and performance standards and the development of an objective, 
transparent, online peer review process (Judson et al., 2013). 
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We believe most strongly that any superior system must be based on 
human biology, and if that aim is compromised, predictive value is bound to 
fall. Advocates of animal testing say that this is unrealistic, and that it is not 
possible to gain sufficient understanding of the intact human system from 
isolated cells and tissues. However, if we look at other fields of technology, 
such as computing, automotive manufacture, telephonic communication, or 
space exploration, we see that yesterday's impossibility becomes today's chal­
lenge and tomorrow's commonplace. There is no reason why this should not 
equally apply to safety testing. In all other areas, technological advances are 
made in a step-wise fashion, seldom, if ever, in a single leap. We argue that the 
only practical way forward is a process of pragmatic evaluation of new tech­
nologies, whereby those that demonstrate success in predicting safety issues 
for humans, where the current system failed (as well as where it succeeded), 
should be accepted for use in appropriate circumstances and with sufficient 
justification. This approach will be iterative, and as shortcomings of the new 
tests are identified, further tests may be developed to overcome these prob­
lems. The truth is that we may never identify tests that will allow prediction 
of all safety issues, but by tackling these in a manageable fashion, we will get 
much closer than we can currently manage using animal-based approaches. 
Of course, we cannot test potential new medicines on humans prospec­
tively, using new methods in place of old ones, in case they perform less well. 
Therefore, new methods must be evaluated using historical "legacy" data. By 
studying the safety profiles of drugs that have been extensively used in hu­
man subjects, which will have necessarily passed the mandatory animal-based 
safety tests, we can identify where those tests failed to detect safety issues in 
human subjects. A selection of drugs whose toxicities were missed by animal 
tests can then form the basis of a test panel, to be submitted to a range of non­
animal tests. In this way, the predictive performance of the new tests can be 
compared to that of the animal-based methods. To increase the scientific rigor 
of such studies, pairs of closely-related compounds should be used, where one 
has a particular toxicity that the other does not share. This will identify tests 
that are capable of differentiating between toxic and non-toxic compounds, 
the key attribute of any desirable test. Rather than assessing each new test in 
isolation, different types of tests will be combined in testing batteries, designed 
to complement each other in their ability to detect a variety of toxicities. Dif­
ferent batteries will be appropriate for different types of compounds. We need 
to forget the beguilingly simplistic approach of attempting to model humans 
with one system, even when that system is an integrated whole animal. No 
single test, however integrated, will ever be an adequate model for the breadth 
of human genetic variability. Combinations of tests at the molecular, cellu­
lar, organ, and system levels will need to be performed to generate sufficient 
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confidence to advance into cautious first-in-human testing, using safe ap­
proaches, such as microdosing, before proceeding to test therapeutic doses in 
patients in carefully designed adaptive clinical trials. 
The Evidence-Based Toxicology Collaboration (EBTC) at the Johns Hopkins 
Bloomberg School of Public Health, is currently undertaking an evidence­
based evaluation study, as described above. Using systematic reviews, they are 
comparing drug-induced toxicity in humans to preclinical animal data and to 
in vitro data from the Toxicity Forecaster (ToxCast) program of the us Envi­
ronmental Protection Agency. The results will provide an objective compari­
son of the relative predictive abilities of animal versus non-animal methods. 
If successful, this study will demonstrate that a limited compound set can be 
used, if proper negative and positive controls are present, to compare the per­
formance of a battery of tests relative to the current system. A clear demon­
stration of multiple successes, especially where the current regime has failed, 
would create a powerful impetus for governments and pharmaceutical com­
panies to allocate more resources to tackling this problem more urgently. Sub­
stantial funding is required, as is greatly increased access to data. 
Pharmaceutical companies are sitting on a treasure trove of preclinical and 
clinical data, which could yield immensely valuable information if made avail­
able for analysis. Former FDA Commissioner, Robert Califf called for a preclini­
cal database to be established (Scott, 2016). This initiative must be seized; it 
has the potential to save time, money, and animals by avoiding futile repetitive 
testing; and, more importantly, the potential to revolutionize the evaluation 
of both old and new technologies, through statistical comparisons with a gold 
mine of millions of data points. 
g Regulatory Change 
Former NIH Director, Elias Zerhouni, and former FDA Commissioner, Marga­
ret Hamburg, state that the "regulation of drugs can either grease the wheels 
of progress or throw a wrench in the works" (Zerhouni and Hamburg, 2016). 
Calling for global harmonization of regulatory requirements, they note that 
differences between regulations in different countries create unnecessary 
barriers to the efficient delivery of safe, innovative, and effective treatments 
to patients. They acknowledge that regulatory authorities are struggling to 
keep up with rapid advances in science and technology and advocate high­
level cooperation to ensure progress is not delayed by bureaucratic stagna­
tion that promotes the status quo. Change needs to be driven by a top-down 
strategy to drive harmonization forward, urgently (Zerhouni and Hamburg, 
2016). 
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Decades-old regulations have not been updated to reflect rapid advances 
in science and technology. It is acknowledged that regulations requiring the 
use of animal tests are a major barrier to adoption and use of more predic­
tive human-relevant test methods (Malloy, 2016). Without regulatory updates 
reflecting the acceptability of the most predictive test methods available, the 
scientific advancements of the past decade will not be utilized. 
International guidelines for preclinical testing remain focused on the use of 
traditional animal tests and merely mention the availability of more predictive 
human-relevant test methods. The International Council for Harmonisation of 
Technical Requirements for Pharmaceuticals for Human Use (1ctt), Guidance 
on Nonclinical Safet:y Studies for the Conduct of Human Clinical Trials and Mar­
keting Authorization for Pharmaceuticals, states: "The development of a phar­
maceutical is a stepwise process involving an evaluation of both animal and 
human efficacy and safety information" (ICH, 2009).  While the ICH guideline 
states that consideration should be given to the 3Rs, specifically reduction of 
the use of animals, and suggests consideration of the use of in vitro methods 
that could possibly replace animals, it does not discuss specifics of acceptable 
non-animal methods. This focus on reduction of animal use addresses only the 
ethics of animal testing, not the safety of human patients. From a public health 
perspective, the focus must be shifted to the replacement of animal tests with 
human-relevant test methods to provide safer, more effective medicines. 
One has only to look at the FDA regulations on investigational new drugs and 
devices to understand the regulatory barrier to acceptance and adoption of 
modern test methods. FDA claims that the regulations give them the flexibility 
to accept modern, non-animal test methods (NATMs), such as in vitro studies, 
or prior experience with the drug or biological product in humans (Dorsey, 
2010 ); however, current FDA regulations explicitly require animal testing. This 
requirement discourages the use of NATMs, which may be more predictive of 
human response. Twenty-nine FDA regulations clearly require animal testing 
and promote the status quo, creating an unreceptive environment that fails to 
encourage innovation and development of more predictive test methods ( Cen­
ter for Responsible Science, 2015). Modification of regulatory language would 
promote use of existing modern test methods and encourage further devel­
opment to advance modernization of preclinical testing. Regulations must be 
changed to state clearly that the test most predictive of human response should 
( or even must) be used. In 2015, a coalition of non-profits, technology develop­
ers, and patient advocacy groups petitioned the FDA to make modest, non­
controversial regulation amendments that would be an important first step 
in advancing the use of NATMs (Center for Responsible Science, 2015). These 
minor amendments to outdated existing regulations would have great impact 
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on the use and development of better tools for drug and device development. 
For example, when a current regulation states, " . . .  extensive animal and clinical 
tests are required as a condition of approval," the petition proposes a change 
of wording to state, " ... extensive preclinical and clinical tests are required as a 
condition of approval. " Adoption of these test-neutral, conservative regulatory 
amendments would be an important first-step in moving forward. The FDA has 
yet to provide a substantive response to the petition. 
While the us is a world leader in biomedical research and technology 
development, it lagged behind the EU in developing a strategy and road­
map for the advancement and use of new technology, until very recently. In 
December 2017, the FDA's Predictive Toxicology Roadmap was issued to advance 
predictive toxicology in regulatory risk assessments (FDA, 2017). In January 
2018, after considering input from 16 federal agencies, the Interagency Coordi­
nating Committee on the Validation of Alternative Methods (1ccvAM) issued 
its Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of 
Chemicals and Medical Products in the United States ( I c CVAM, 2018 ). Both road­
maps outline a way forward to successful implementation of new technology. 
Crucially, they have been issued by government agencies, which should ensure 
that real progress is achieved; indeed, many activities towards implementation 
are already underway. The European roadmap calls for many things, including 
a joint taskforce to gather all current data on a wide variety of compounds into 
a toxicity database; abolition of useless tests; and, crucially, reasonable invest­
ment (Basketter et al., 2012). However, without an effective top-down (i.e., gov­
ernment-led) implementation strategy, advances in science and technology 
will languish and the Eu will lag behind. 
Evidence shows that animal methods are often still used, both in the us 
and the EU, even when superior validated methods are available. This is like­
ly due to existing regulations that explicitly require animal tests. Applicants 
worry that forgoing the inclusion of animal data in product submissions risks 
rejection by regulatory reviewers, which would be costly in time and expense 
for drug sponsors. For example, since 2005, the FDA has informally stated 
that Draize data are not required for primary skin and eye irritation testing; 
yet, drug sponsors continue to submit Draize data. A review of the 137 New 
Molecular Entities approved by the FDA between 2011-2014 showed that the 
Draize test was used in 94°/o of all skin irritation and 60% of all eye irritation 
tests, despite the availability of validated methods that are more predictive of 
human response (Archibald, Drake and Coleman, 2015). 
Regulatory submission reviewers require continuing education to be up 
to date on available new technologies. Without reviewer education and uni­
form acceptance criteria, variability between reviewers' acceptance of new 
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technologies will discourage their use and cause confusion for sponsors on 
their acceptability. It is essential that regulators become knowledgeable about 
available NATMs to facilitate early communication with sponsors on their 
acceptability. 
10 Conclusions 
There is a clear ethical imperative to replace unreliable animal-based safety 
tests, not just for the animals but to protect human safety. Remarkable knowl­
edge and tools are emerging from projects, such as ToxCast; To:x21; Innovative 
Medicines Initiative; Safety Evaluation Ultimately Replacing Animal Testing 
(SEURAT); Integrated European "Flagship" Program Driving Mechanism-based 
Toxicity Testing and Risk Assessment for the 21st Century (EU-ToxRisk); and 
the Precision Medicines Initiative. These initiatives have the potential to revo­
lutionize our ability to advance and protect human health, but only if they 
are implemented. A 2018 report by the UK Biolndustry Association and the 
Medicines Discovery Catapult emphasizes that humanizing the process of drug 
discovery and testing is the most important way to ease the productivity crisis 
in pharmaceutical research. 
We must acknowledge that predicting the safety of medicines is an enor­
mous challenge, and that a major obstacle to paradigm change is lack of con­
fidence in the new methods. To tackle this, we suggest that a new, pragmatic 
approach to demonstrating that novel methods are more fit for purpose than 
existing methods could help to accelerate the replacement of most, if not all, 
animal toxicity tests with superior tests based on human biology. We believe 
that only through utilizing human-based systems to evaluate new medicines 
can we truly gain confidence in their clinical safety. In a 2014 debate on the 
proposal that "Animal experimentation in toxicology can be phased out in 
five-years' time," there was unanimous agreement that disruptive technolo­
gies must be properly funded and that more systematic, comparative data is 
needed (van der Meer, 2014). 
In 2007, the us National Research Council called for a "paradigm shift from 
the use of experimental animals [ . . .  ] toward the use of more efficient in vitro 
tests and computational techniques" in their landmark report, Toxicity Testing 
in the 21st Century: A Vision and a Strategy. The authors expected the paradigm 
shift to encounter resistance, as toxicological testing practices are "deeply in­
grained." They envisioned that "toxicity testing will be radically overhauled 
over the next 10 years, with the animal testing component virtually, if not actu­
ally, eliminated within the next 20 years" (National Research Council, 2007). 
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The science of toxicity testing has indeed been transformed over the past 10 
years; but in the absence of any regulatory pressure, practical change has been 
occurring at a glacial pace, while revolution rather than evolution is required 
(Hartung, 2017 ). Deadlines create tremendous impetus for change, as can be 
seen with the EU Cosmetic and Registration, Evaluation, Authorisation and Re­
striction of CHemicals (REACH) regulations. If we are serious about reducing 
the ever-increasing burden of death and disability caused by ADRs, we must 
agree on a deadline for the adoption of more human-relevant methods, and the 
phasing out of methods whose predictive ability has not been proven. As with 
the replacement of horses by cars, there will need to be a brief period of shar­
ing the road, while confidence in the new methods grows. The Netherlands now 
leads the world with its announcement that it intends to phase out all legally 
prescribed, animal-based safety testing by 2025 (Netherlands National Com­
mittee for the protection of animals used for scientific purposes, NC ad, 2016). 
The Committee recognizes that the transition will not happen of its own ac­
cord and will require clear strategic direction to change attitudes and practices. 
Crucially, the regulations that govern how drugs are tested must be updated 
to encourage the adoption of the best new approaches. Current regulations are 
stifling innovation by failing to keep pace with scientific progress. We argue 
that several aspects of current practice can no longer be justified: 
1. The continued use of testing methods that have never been validated, 
while novel methods must demonstrate a level of performance that cur­
rent methods not only have never been asked to perform but are clearly 
unable to perform. 
2. Resistance to the adoption of non-animal methods that, although not 
formally validated, show greater predictive performance than animal 
tests. 
3. The continued blind eye turned to the use of animal-based tests, where 
viable non-animal methods exist, on the pretext that they may be 
required by regulators at home or abroad. 
4. The exposure of human patients and volunteers to potentially unsafe 
substances on the basis of demonstrably unreliable animal data. 
5. The risk of the loss of potentially life-saving/modifying treatments on the 
basis of demonstrably unreliable animal data. 
In March 2016, Safer Medicines Trust commissioned a survey of 2,500 UK 
healthcare professionals. 79°/o agreed that pharmaceutical companies should 
be legally obliged to test new medicines using methods demonstrated to be 
the most predictive of safety for humans (Dods Information, 2016). Govern­
ments must act to protect the public by updating regulations, whose raison 
d'etre is patient safety, that now prevent their own aim from being realized. 
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